Dermata Therapeutics, Inc. (DRMA) Form 8-K — May 27, 2026
$DRMAForm 8-KItems 5.02, 5.07, 9.01Filed May 27, 2026, 4:57 PM ET0001493152-26-025441Original filing
Dermata Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on May 27, 2026, where shareholders approved several key governance and capital structure proposals. Approximately 59% of outstanding shares were represented at the meeting, providing sufficient voting power to pass all items. Shareholders elected David Hale, Steven Mento, Ph.D., and Brittany Bradrick as Class II directors and ratified the appointment of CBIZ CPAs P.C.
Key figures
- Shares Outstanding
- 4,022,144
- Warrants Repriced
- 120,734
- Percent Shares Represented
- 59%
- Equity Plan Shares Authorized
- 402,214
- Shares Represented At Meeting
- 2,374,471
- Prior Equity Plan Shares Authorized
- 153,586
Price after filing
1 day: +3.8%7 days: -2.3%30 days: -10.0%
Close on the filing date to close N calendar days later (from $1.30). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.